SEARCH:   Advanced

Blood, 1 June 2006, Vol. 107, No. 11, pp. 4508-4513. Prepublished online as a Blood First Edition Paper on February 21, 2006; DOI 10.1182/blood-2005-08-3451. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-08-3451v1 107/11/4508    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Loh, M. L. Articles by Gilliland, D. G. Search for Related Content PubMed PubMed Citation Articles by Loh, M. L. Articles by Gilliland, D. G. Related Collections Neoplasia Oncogenes and Tumor Suppressors Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01 Mignon L. Loh, Meredith A. Goldwasser, Lewis B. Silverman, Wing-Man Poon, Shashaank Vattikuti, Angelo Cardoso, Donna S. Neuberg, Kevin M. Shannon, Stephen E. Sallan, and D. Gary Gilliland From the Department of Pediatrics, Comprehensive Cancer Center, University of California, San Francisco; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium, Boston, MA; Children's Hospital, Boston, MA; Brigham and Women's Hospital, Boston, MA; and Howard Hughes Institute of Medicine, Boston, MA. In a retrospective analysis, we previously reported that children whose leukemia cells harbored the TEL/AML1 gene rearrangement have excellent outcomes. From 1996 to 2000, we conducted a prospective study to determine the incidence and outcomes of children with TEL/AML1-positive acute lymphoblastic leukemia (ALL). Children with newly diagnosed ALL were treated on DFCI ALL Consortium Protocol 95-01. Patients were risk stratified primarily by current National Cancer Institute (NCI)–Rome risk criteria. With a median follow-up of 5.2 years, the 5-year event-free survival for TEL/AML1-positive patients was 89% compared with 80% for TEL/AML1-negative B-precursor patients (P = .05). The 5-year overall survival rate was 97% among TEL/AML-positive patients compared with 89% among TEL/AML1-negative patients (P = .03). However, in a multivariable analysis, risk group (age and leukocyte count at diagnosis) and asparaginase treatment group, but not TEL/AML1 status, were found to be independent predictors of outcome. We conclude that TEL/AML1-positive patients have excellent outcomes, confirming our previous findings. However, factors such as age at diagnosis and presenting leukocyte count should be taken into consideration when treating this group of patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. E. Rubnitz, D. Wichlan, M. Devidas, J. Shuster, S. B. Linda, J. Kurtzberg, B. Bell, S. P. Hunger, A. Chauvenet, C.-H. Pui, et al. Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study J. Clin. Oncol., May 1, 2008; 26(13): 2186 - 2191. [Abstract] [Full Text] [PDF] J. Zhou, M. A Goldwasser, A. Li, S. E. Dahlberg, D. Neuberg, H. Wang, V. Dalton, K. D McBride, S. E. Sallan, L. B Silverman, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01 Blood, September 1, 2007; 110(5): 1607 - 1611. [Abstract] [Full Text] [PDF] E. Barry, D. J. DeAngelo, D. Neuberg, K. Stevenson, M. L. Loh, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, et al. Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols J. Clin. Oncol., March 1, 2007; 25(7): 813 - 819. [Abstract] [Full Text] [PDF] A. Moghrabi, D. E. Levy, B. Asselin, R. Barr, L. Clavell, C. Hurwitz, Y. Samson, M. Schorin, V. K. Dalton, S. E. Lipshultz, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia Blood, February 1, 2007; 109(3): 896 - 904. [Abstract] [Full Text] [PDF] N. J. Lacayo, J. F. DiMartino, M. C. Wei, and G. V. Dahl CpG Island Methylator Phenotype and Childhood Leukemia. Clin. Cancer Res., August 15, 2006; 12(16): 4787 - 4789. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020